Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer

被引：0
|
作者：
Ghosh, Jaya [1 ]
Kumar, Lalit [1 ]
机构：
[1] All India Inst Med Sci, Dept Med Oncol, New Delhi 110029, India
来源：
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2008年 / 29卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / U37
页数：4
相关论文
共 50 条
  • [1] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [3] A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
    Liu, J. F.
    Herold, C.
    Luo, W.
    Penson, R.
    Horowitz, N.
    Konstantinopoulos, P.
    Castro, C.
    Curtis, J.
    Matulonis, U. A.
    Cannistra, S.
    Dizon, D. S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Hagemann, Andrea R.
    Novetsky, Akiva P.
    Zighelboim, Israel
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Wright, Jason D.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 535 - 540
  • [5] Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer
    Zighelboim, Israel
    Wright, Jason D.
    Gao, Feng
    Case, Ashley Stephens
    Massad, L. Stewart
    Mutch, David Gardner
    Powell, Matthew A.
    Thaker, Premal H.
    Eisenhauer, Eric Lawernce
    Cohn, David E.
    Valea, Fidel A.
    Secord, Angeles Alvarez
    Lippmann, Lynne T.
    Rader, Janet Sue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] PHASE II TRIAL OF PACLITAXEL, CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT OR PERSISTENT CERVICAL CANCER
    Suzuki, K.
    Nagao, S.
    Kaneda, M.
    Sibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Sudo, T.
    Yamaguchi, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 411 - 411
  • [7] PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER
    Secord, A. Alvarez
    McCollum, M.
    Davidson, B.
    Broadwater, G.
    Squatrito, R.
    Havrilesky, L.
    Gabel, A.
    Nixon, A.
    Duska, L.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 457 - 457
  • [8] Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
    Secord, Angeles Alvarez
    McCollum, Michael
    Davidson, Brittany A.
    Broadwater, Gloria
    Squatrito, Robert
    Havrilesky, Laura J.
    Gabel, Anne C.
    Starr, Mark D.
    Brady, J. Chris
    Nixon, Andrew B.
    Duska, Linda R.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 555 - 561
  • [9] A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
    Ling, Huichung Tina
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study.
    Burger, RA
    Sill, M
    Monk, BJ
    Greer, B
    Sorosky, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 457S - 457S
12345